A preclinical stage biotechnology company developing precision immuno-oncology therapeutics targeting a novel pathway.

NextPoint is developing multiple therapies with first in class potential for patients with solid tumors who lack viable treatment options. While immune checkpoint inhibitors have revolutionized cancer treatments, as many as 80% of patients do not benefit from these medications. NextPoint is targeting a novel checkpoint pathway (B7 axis), which is independent to PD-L1, and has the potential to prevent these hard-to-treat cancers from avoiding detection by the immune system.